^○Soo-Jin Kim ¹, Takashi Yoshikado ¹, Ichiro Ieiri ², Kazuya Maeda ³, Miyuki Kimura ⁴, Shin Irie ⁴, Hiroyuki Kusuhara ³, Yuichi Sugiyama ¹ (1.Sugiyama Lab., RIKEN Innovation Center, RIKEN, 2.Department of Clinical Pharmacokinetic, Graduate School of Pharmaceutical Sciences, Kyushu University, 3.Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 4.Sugioka Memorial Hospital)

^○Takashi Yoshikado ¹, Sawako Furihata ², Hanano Terashima ³, Takeshi Nakayama ³, Keiko Ishigame ¹, Kazunobu Tsunemoto ¹, Kazuya Maeda ³, Hiroyuki Kusuhara ³, Kenichi Furihata ², Yuichi Sugiyama ¹ (1.Sugiyama Laboratory, RIKEN Innovation Center, RIKEN, 2.P-One Clinic, Keikokai Medical Corporation, 3.Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo)

^○Ryuta Asaumi , Kenichi Nunoya ¹, Haruo Imawaka ¹, Yuichi Sugiyama ² (1.Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co.,Ltd., 2.Sugiyama Laboratory, RIKEN Innovation Center, RIKEN)

^○Aoi Matsushima ¹, Keisuke Oda ², Nobuhiro Mori ¹, Teruo Murakami ^1,2 (1.Graduate School of Pharmaceutical Sciences, Hiroshima International University, 2.Faculty of Pharmaceutical Science, Hiroshima International University)